| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 6.02▲ | 6.06▼ | 6.04▼ | 5.83▲ | 5.51▲ |
| MA10 | 6.02▲ | 6.04▼ | 6.03▲ | 5.71▲ | 5.29▲ |
| MA20 | 6.06▼ | 6.04▲ | 5.94▲ | 5.52▲ | 5.35▲ |
| MA50 | 6.05▼ | 5.85▲ | 5.72▲ | 5.28▲ | 5.11▲ |
| MA100 | 6.03▲ | 5.69▲ | 5.61▲ | 5.47▲ | 3.41▲ |
| MA200 | 5.96▲ | 5.59▲ | 5.35▲ | 5.64▲ | 5.26▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.005▼ | -0.011▼ | -0.006▼ | 0.053▲ | 0.032▲ |
| RSI | 47.868▼ | 55.103▲ | 58.675▲ | 62.594▲ | 56.479▲ |
| STOCH | 27.429 | 62.932 | 53.858 | 71.431 | 65.137 |
| WILL %R | -60.870 | -44.445 | -42.857 | -17.308▲ | -9.626▲ |
| CCI | -20.634 | 8.842 | 0.884 | 186.426▲ | 200.158▲ |
| CDL | $IMRX Dark Cloud Cover Candlestick Pattern Detected | Set Alert |
|
Wednesday, April 22, 2026 02:10 PM
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that ...
|
|
Tuesday, April 21, 2026 02:46 PM
New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO presentation ...
|
|
Monday, April 20, 2026 05:59 AM
Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 24/04/26 | 6.17 | 6.22 | 5.815 | 6.04 | 730,421 |
| 23/04/26 | 5.88 | 6.15 | 5.795 | 6.13 | 930,915 |
| 22/04/26 | 5.59 | 5.915 | 5.51 | 5.89 | 894,117 |
| 21/04/26 | 5.52 | 5.715 | 5.47 | 5.55 | 722,627 |
| 20/04/26 | 5.635 | 5.68 | 5.2775 | 5.53 | 709,427 |
| 17/04/26 | 5.73 | 5.85 | 5.5001 | 5.56 | 795,614 |
| 16/04/26 | 5.75 | 5.755 | 5.43 | 5.57 | 1,044,578 |
| 15/04/26 | 5.44 | 5.75 | 5.2513 | 5.75 | 893,606 |
| 14/04/26 | 5.75 | 5.83 | 5.39 | 5.41 | 994,042 |
| 13/04/26 | 5.52 | 5.845 | 5.4803 | 5.70 | 759,020 |
|
|
||||
|
|
||||
|
|